Nasdaq grts.

Gritstone Bio Inc (NASDAQ:GRTS)’s traded shares stood at 0.86 million during the last session, with the company’s beta value hitting 0.59. At the close of trading, the stock’s price was $1.88, to imply an increase of 2.73% or $0.05 in intraday trading. The GRTS share’s 52-week high remains $4.05, putting it -115.43% down since that peak ...

Nasdaq grts. Things To Know About Nasdaq grts.

Find the latest on short interest for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.Find the latest news headlines from Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.Get the latest GRTS (GRTS) real-time quote, historical performance, charts, and ... Home GRTS • NASDAQ. add. Share. GRTS. $1.88. After Hours: $1.93. ( 2.66%)+ ...The Last 12 Months Of Insider Transactions At Gritstone bio. The Executive VP & CTO, Roman Yelensky, made the biggest insider sale in the last 12 months. That single transaction was for US$221k ...EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced... -- 10,000 participant randomized Phase 2b study will evaluate Gritstone s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus ...

Find the latest analyst research for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com. Gritstone bio, Inc. Common Stock (GRTS) Analyst Research | Nasdaq …WebGRTS Historical Data. Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online . The net and ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical ...

EMERYVILLE, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Dec 1, 2023 · The following insider purchased GRTS shares in the last 24 months: Vassiliki Economides ($22,800.00). How much insider buying is happening at Gritstone bio? Insiders have purchased a total of 12,000 GRTS shares in the last 24 months for a total of $22,800.00 bought.

Gainers. Inpixon (NASDAQ:INPX) shares rose 44.6% to $0.2023 in pre-market trading after gaining around 10% on Wednesday.; Gritstone bio, Inc. (NASDAQ:GRTS) shares rose 37% to $1.63 in pre-market ...Gritstone Bio Inc (NASDAQ:GRTS) trade information. Sporting -3.50% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 11/13/23 when the GRTS stock price touched $1.38 or saw a rise of 25.61%.10 ต.ค. 2566 ... EMERYVILLE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims ...Oct 30, 2023 · In the last trading session, 1.12 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.61. With the company’s per share price at $1.89 changed hands at -$0.06 or -3.08% during last session, the market valuation stood at $175.92M. GRTS’s last price was a

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

The following insider purchased GRTS shares in the last 24 months: Vassiliki Economides ($22,800.00). How much insider buying is happening at Gritstone bio? Insiders have purchased a total of 12,000 GRTS shares in the last 24 months for a total of $22,800.00 bought.

EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Aug 31, 2023 · As of August 31, 2023, the average one-year price target for Gritstone Bio is 8.77. The forecasts range from a low of 2.02 to a high of $21.00. The average price target represents an increase of ... Aug 9, 2023 · Second Quarter 2023 Financial Results. Cash, cash equivalents, marketable securities and restricted cash were $122.3 million as of June 30, 2023, compared to $185.2 million as of December 31, 2022 ... EMERYVILLE, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...As of August 31, 2023, the average one-year price target for Gritstone Bio is 8.77. The forecasts range from a low of 2.02 to a high of $21.00. The average price target represents an increase of ...

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...marketbeat.com - July 5 at 5:00 AM. Gritstone bio (NASDAQ:GRTS) shareholders have endured a 70% loss from investing in the stock three years ago. finance.yahoo.com - July 4 at 10:02 AM. Board Member at Gritstone Bio Acquires Company Stock Options Worth 51,800 Shares. benzinga.com - June 22 at 11:42 PM.Nov 10, 2023 · During the recent session, Gritstone Bio Inc (NASDAQ:GRTS)’s traded shares were 0.46 million, with the beta value of the company hitting 0.56. At the last check today, the stock’s price was $1.46, reflecting an intraday loss of -6.73% or -$0.1. The 52-week high for the GRTS share is $4.05, that ... EMERYVILLE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS ), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study ...Gritstone bio, Inc. (GRTS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 1.3100 -0.0100 (-0.76%) As of 03:13PM EST. Market open. 1d 5d 1m 6m YTD 1y 5y Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product ...

May 6, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Get Gritstone Oncology Inc (GRTS) share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial ...

Aug 4, 2022 · Second Quarter 2022 Financial Results. Cash, cash equivalents, marketable securities and restricted cash were $159.2 million as of June 30, 2022, compared to $223.5 million as of December 31, 2021 ... Nov 24, 2023 · Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ... Oct 25, 2022 · EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ... 16 พ.ค. 2566 ... HC Wainwright & Co. Reiterates Gritstone Bio (GRTS) Buy Recommendation ... Fintel reports that on May 15, 2023, HC Wainwright & Co. reiterated ...The average price predicted for Gritstone Bio Inc (GRTS) by analysts is $10.40, which is $9.08 above the current market price. The public float for GRTS is 87.55M, and at present, short sellers hold a 9.62% of that float. On November 30, 2023, the average trading volume of GRTS was 2.33M shares. The electric vehicle boom is accelerating – …EMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...On November 8, 2023, Gritstone Bio Inc ( NASDAQ:GRTS ), a clinical-stage biotechnology company, announced its financial results for the third quarter ended September 30, 2023, along with updates ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced... -- 10,000 participant randomized Phase 2b study will evaluate Gritstone s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus ...Gracell Biotechnologies Inc. (NASDAQ:GRCL), Blue Ridge Bankshares, Inc. (NYSE:BRBS), Gritstone bio, Inc. (NASDAQ:GRTS), and Ebix, Inc. (NASDAQ:EBIX) are some best stocks for day trading. Click ...

The average one-year price target for Gritstone Bio (NASDAQ:GRTS) has been revised to 10.71 / share. This is an increase of 22.09% from the prior estimate of 8.77 dated August 31, 2023.

The average price predicted for Gritstone Bio Inc (GRTS) by analysts is $10.40, which is $9.08 above the current market price. The public float for GRTS is 87.55M, and at present, short sellers hold a 9.62% of that float. On November 30, 2023, the average trading volume of GRTS was 2.33M shares. The electric vehicle boom is accelerating – and ...

Gritstone Bio Inc (NASDAQ:GRTS) trade information. Sporting -3.50% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 11/13/23 when the GRTS stock price touched $1.38 or saw a rise of 25.61%. Year-to-date, Gritstone Bio Inc shares have moved -60.00%, while the 5-day ...May 6, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Find the latest Insider Activity data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com. Insiders seem to have made the most of their holdings by selling US$221k worth of Gritstone bio, Inc. (NASDAQ:GRTS) stock at an average sell price of US$22.10 during the past year. The company's ...Gritstone Bio Inc (NASDAQ: GRTS)’s stock price has soared by 17.69 in relation to previous closing price of 1.30. Nevertheless, the company has seen a gain of 11.68% in its stock price over the last five trading days. Zacks Investment Research reported 2023-10-16 that Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Track Gritstone Bio Inc (GRTS) Stock Price, Quote, latest community messages, chart, news and other stock related information.Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone ...Nov 7, 2023 · About Gritstone bio Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and ... 20 ม.ค. 2564 ... (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, and ...Gritstone bio (GRTS) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. ... GRTS: NASDAQ: Common Stock Price Change Change ...EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...

EMERYVILLE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Find the latest Insider Activity data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com. Gritstone bio, Inc. (NASDAQ:GRTS) shares rose 37% to $1.63 in pre-market trading after the company announced it was awarded a BARDA contract to conduct a Phase 2b comparative study evaluating a ...Instagram:https://instagram. nasdaq fcel financialsvangaurd 2050best gold buying companyai option EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...American International Group Inc. purchased a new stake in Gritstone bio, Inc. (NASDAQ:GRTS – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 42,245 shares of the company’s stock, valued at approximately $82,000. Other large investors have also recently added to or … apph newsinvest in art online Gracell Biotechnologies Inc. (NASDAQ:GRCL), Blue Ridge Bankshares, Inc. (NYSE:BRBS), Gritstone bio, Inc. (NASDAQ:GRTS), and Ebix, Inc. (NASDAQ:EBIX) are some best stocks for day trading. Click ...Jul 15, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. forex discord GRTS Historical Data. Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online . The net and ...Follow. EMERYVILLE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines ...Data for this list was collected on October 13, 2021, using TradingView’s stock screener, and all top NASDAQ genetics stocks had market caps between US$50 million and US$500 million at that time. 1.